荣昌生物(09995.HK)维迪西妥单抗获国家药监局批准上市

阿斯达克财经
11 May

荣昌生物(09995.HK) 公布,注射用维迪西妥单抗(商品名︰爱地希)正式获中国国家药品监督管理局上市的批准,用于治疗HER2阳性且存在肝转移的晚期乳腺癌的患者。维迪西妥单抗是公司研发的中国首个原创抗体偶联药物,以肿瘤表面的HER2蛋白为靶点,能精准识别和杀伤肿瘤细胞。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10